Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
RESEARCH TOOLSreports
Harmony Biosciences Holdings (HRMY) Stock Price & Analysis
172 Followers
HRMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.61 - $39.27
Previous Close$32.04
Volume325.92K
Average Volume (3M)406.72K
Market Cap
$1.82B
Enterprise Value$1.66B
Total Cash (Recent Filing)$353.46M
Total Debt (Recent Filing)$193.57M
Price to Earnings (P/E)13.8
Beta0.70
Next Earnings
Jul 30, 2024EPS Estimate
$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding56,791,861
10 Day Avg. Volume371,314
30 Day Avg. Volume406,719
Standard Deviation0.13
R-Squared0.07
Alpha-0.00311
Financial Highlights & Ratios
Price to Book (P/B)5.19
Price to Sales (P/S)2.94
Price to Cash Flow (P/CF)5.60
P/FCF Ratio4.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.85
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda9.30
Forecast
1Y Price Target
$44.50Price Target Upside38.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences Executive Resigns, Subsidiary Renamed
PremiumCompany Announcements
Harmony Biosciences Unveils Investor Presentation with Future Insights
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company expects one new product launch every year over the next five years.
Regulatory ApprovalFDA approval for Wakix in pediatric patients with narcolepsy builds overall confidence in the asset duration for Wakix.
Safety And EfficacyFDA denial of a Citizen's Petition filed by Scorpion Capital helps to remove a final short report-related overhang on the stock.
Bears Say
Growth ConcernsThe sustainability of both the near-term and longer-term growth for pitolisant/Wakix is being debated by investors.
Pipeline DiversificationPipeline diversification efforts fall short in our view.
Regulatory IssuesHRMY received a complete response letter (i.e., did not receive approval) for Wakix to treat cataplexy in pediatric narcolepsy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HRMY FAQ
What was Harmony Biosciences Holdings’s price range in the past 12 months?
Harmony Biosciences Holdings lowest stock price was $18.61 and its highest was $39.27 in the past 12 months.
What is Harmony Biosciences Holdings’s market cap?
Currently, no data Available
When is Harmony Biosciences Holdings’s upcoming earnings report date?
Harmony Biosciences Holdings’s upcoming earnings report date is Jul 30, 2024 which is in 9 days.
How were Harmony Biosciences Holdings’s earnings last quarter?
Harmony Biosciences Holdings released its earnings results on Apr 30, 2024. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.604 by $0.066.
Is Harmony Biosciences Holdings overvalued?
According to Wall Street analysts Harmony Biosciences Holdings’s price is currently Undervalued.
Does Harmony Biosciences Holdings pay dividends?
Harmony Biosciences Holdings does not currently pay dividends.
What is Harmony Biosciences Holdings’s EPS estimate?
Harmony Biosciences Holdings’s EPS estimate is $0.01.
How many shares outstanding does Harmony Biosciences Holdings have?
Harmony Biosciences Holdings has 56,791,862 shares outstanding.
What happened to Harmony Biosciences Holdings’s price movement after its last earnings report?
Harmony Biosciences Holdings reported an EPS of $0.67 in its last earnings report, beating expectations of $0.604. Following the earnings report the stock price went up 5.675%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings?
Among the largest hedge funds holding Harmony Biosciences Holdings’s share is Royce & Associates LLC. It holds Harmony Biosciences Holdings’s shares valued at 3M.
---
Harmony Biosciences Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.50 (38.89% Upside)
$44.50 (38.89% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 126.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.89%
12-Months-Change
Fundamentals
Return on Equity
28.73%
Trailing 12-Months
Asset Growth
18.44%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
---
HRMY Company Deck
---
HRMY Earnings Call
Q1 2024
0:00 / 0:00
---
HRMY Stock 12 Month Forecast
Average Price Target
$44.50
▲(38.89% Upside)
Technical Analysis
Best Analysts Covering HRMY
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+3.97%
reiterated a buy rating 28 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +3.97% per trade.
---